Clinical Trial Update: Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038) [Phase 2]

View source ↗

Summary

A Phase 2 extension trial of ridaforolimus (deforolimus, MK-8669) in participants with advanced cancer has been terminated and results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Ridaforolimus (ridaforolimus)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Advanced Cancers | Phase 2 | Status: TERMINATED | Results posted: 2018-05-03